Serina Therapeutics (NYSEAMERICAN:SER) Director Richard Peter Marshall Acquires 12,183 Shares

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Director Richard Peter Marshall purchased 12,183 shares of the stock in a transaction on Tuesday, May 19th. The stock was acquired at an average cost of $1.65 per share, with a total value of $20,101.95. Following the acquisition, the director owned 12,183 shares of the company’s stock, valued at approximately $20,101.95. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Serina Therapeutics Stock Performance

Shares of NYSEAMERICAN SER opened at $1.98 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18. The firm has a market capitalization of $29.70 million, a P/E ratio of -0.99 and a beta of 1.15. The business has a 50-day simple moving average of $1.95. Serina Therapeutics, Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $7.92.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.